ADC Therapeutics (ADCT) to Release Quarterly Earnings on Tuesday

ADC Therapeutics (NYSE:ADCT) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.36) per share and revenue of $17.82 million for the quarter.

ADC Therapeutics (NYSE:ADCT) last issued its earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $23.03 million during the quarter, compared to analyst estimates of $17.71 million. On average, analysts expect ADC Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

ADC Therapeutics Price Performance

Shares of ADC Therapeutics stock opened at $2.71 on Friday. ADC Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $3.97. The firm has a market capitalization of $268.78 million, a P/E ratio of -1.87 and a beta of 1.92. The company’s 50 day moving average price is $3.07 and its two-hundred day moving average price is $2.09.

Hedge Funds Weigh In On ADC Therapeutics

An institutional investor recently raised its position in ADC Therapeutics stock. AQR Capital Management LLC increased its position in shares of ADC Therapeutics SA (NYSE:ADCT) by 411.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 201,170 shares of the company’s stock after buying an additional 161,808 shares during the period. AQR Capital Management LLC owned 0.20% of ADC Therapeutics worth $284,000 at the end of the most recent reporting period. Institutional investors own 41.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. Royal Bank Of Canada raised shares of ADC Therapeutics from an “outperform” rating to a “moderate buy” rating and dropped their price target for the company from $8.00 to $5.00 in a research note on Friday, June 20th. Guggenheim reaffirmed a “buy” rating and set a $10.00 price target (up previously from $7.00) on shares of ADC Therapeutics in a research note on Friday, June 13th. Four equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $7.75.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.